论文部分内容阅读
为探讨蝎素抗癌因子（ＡＦＳＶＣ－Ⅱ）对癌性胸水的治疗作用，将癌性胸水患者随机分为治疗组２３例，对照组２０例，两组性别、年龄、病程、病理分型等构成比大致相同。在治疗前均未对胸水进行任何治疗，每次胸腔给药时，均在抽尽胸水后进行。治疗组用ＡＦＳＶＣ－Ⅱ０．４ｍｇ加２ｍｌ注射用水稀释后注入，每周２次，每周增加０．４ｍｇ，最大剂量≤１．６ｍｇ。对照组用５－氟尿嘧啶５００ｍｇ，丝裂霉素１６～２０ｍｇ，每周２次，４周后进行比较。结果：治疗组对腺癌引起的胸水的疗效优于对照组（Ｐ＜０．０５），对疼痛、纳差（Ｐ＜０．０１），增加外周白细胞均有显著差异（Ｐ＜０．０５）。提示ＡＦＳＶＣ－Ⅱ对肺癌伴胸水有效。
To investigate the therapeutic effect of AFSVC-Ⅱ on cancerous pleural effusion, patients with cancerous pleural effusion were randomly divided into treatment group (n = 23) and control group (n = 20). The gender, age, course of disease, pathological classification and so on Composition ratio is roughly the same. In the treatment of pleural effusion were not any treatment, each chest administration, are pleural effusion pumping after. The treatment group with AFSVC-Ⅱ 0.4mg plus 2ml diluted with water for injection, twice a week, increasing 0.4mg per week, the maximum dose ≤ 1.6mg. The control group with 500-fluorouracil 500mg, mitomycin 16 ~ 20mg, 2 times a week, 4 weeks after the comparison. Results: The therapeutic effect on pleural effusion caused by adenocarcinoma in the treatment group was better than that in the control group (P <0.05), and there was significant difference between the treatment group and the control group (P <0.05) ). Tip AFSVC-Ⅱ lung cancer with pleural effusion effective.